Sofiane Bendifallah1, Geoffroy Canlorbe2, Emilie Raimond3, Delphine Hudry4, Charles Coutant4, Olivier Graesslin3, Cyril Touboul5, Florence Huguet6, Annie Cortez7, Emile Daraï8, Marcos Ballester8. 1. Department of Obstetrics and Gynecology, Tenon University Hospital, University Pierre and Marie Curie, Paris, France; Department of Epidemiology, Information Systems, and Modeling, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche en Santé 707, University Pierre and Marie Curie, Paris, France. Electronic address: sofiane.bendifallah@yahoo.fr. 2. Department of Obstetrics and Gynecology, Tenon University Hospital, University Pierre and Marie Curie, Paris, France. 3. Department of Obstetrics and Gynecology, Institute Alix de Champagne University Hospital, Reims, France. 4. Centre de Lutte Contre le Cancer Georges François Leclerc, Dijon, France. 5. Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal, Créteil, France. 6. Department of Radiation Oncology, Tenon University Hospital, University Pierre and Marie Curie, Paris, France. 7. Department of Pathology, Tenon University Hospital, University Pierre and Marie Curie, Paris, France. 8. Department of Obstetrics and Gynecology, Tenon University Hospital, University Pierre and Marie Curie, Paris, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche en Santé 938, University Pierre and Marie Curie, Paris, France.
Abstract
OBJECTIVE: The objective of the study was to externally validate and assess the robustness of 2 nomograms designed to predict the probability of lymphatic dissemination (LD) for patients with early-stage endometrioid endometrial cancer. STUDY DESIGN: Using a prospective multicenter database, we assessed the discrimination, calibration, and clinical utility of 2 nomograms in patients with surgically treated early-stage endometrioid endometrial cancer. RESULTS: Among the 322 eligible patients identified, the overall LD rate was 9.9% (32 of 322). Predictive accuracy according to discrimination was 0.65 (95% confidence interval, 0.61-0.69) for the full nomogram and 0.71 (95% confidence interval, 0.68-0.74) for the alternative nomogram. The correspondence between observed recurrence rate and the nomogram predictions suggests a moderate calibration of the nomograms in the validation cohort. CONCLUSION: The nomograms were externally validated and shown to be partly generalizable to a new and independent patient population. Although these tools provide a more individualized estimation of LD, additional parameters are needed to allow higher accuracy for counseling patients in clinical practice.
OBJECTIVE: The objective of the study was to externally validate and assess the robustness of 2 nomograms designed to predict the probability of lymphatic dissemination (LD) for patients with early-stage endometrioid endometrial cancer. STUDY DESIGN: Using a prospective multicenter database, we assessed the discrimination, calibration, and clinical utility of 2 nomograms in patients with surgically treated early-stage endometrioid endometrial cancer. RESULTS: Among the 322 eligible patients identified, the overall LD rate was 9.9% (32 of 322). Predictive accuracy according to discrimination was 0.65 (95% confidence interval, 0.61-0.69) for the full nomogram and 0.71 (95% confidence interval, 0.68-0.74) for the alternative nomogram. The correspondence between observed recurrence rate and the nomogram predictions suggests a moderate calibration of the nomograms in the validation cohort. CONCLUSION: The nomograms were externally validated and shown to be partly generalizable to a new and independent patient population. Although these tools provide a more individualized estimation of LD, additional parameters are needed to allow higher accuracy for counseling patients in clinical practice.
Authors: Noemie Body; Vincent Lavoué; Olivier De Kerdaniel; Fabrice Foucher; Sébastien Henno; Aurélie Cauchois; Bruno Laviolle; Marc Leblanc; Jean Levêque Journal: BMC Cancer Date: 2016-07-19 Impact factor: 4.430